RHHBY Articles, Roche Holding Ltd ADR - From 07/05/24

On Thursday, Roche Holdings AG (OTC:RHHBY) said that the Phase 2/3 SKYSCRAPER-06 study of tiragolumab plus Tecentriq (atezolizumab) and chemotherap...

On Wednesday, the FDA approved Epkinly (epcoritamab-bysp) as the first and only T-cell-engaging bispecific antibody administered subcutaneousl...

Roche (OTC: RHHBY) announced that the European Commission has granted marketing authorization to the subcutaneous formulation of relapsing mul...

The U.S. Supreme Court has supported 21 pharmaceutical and medical equipment companies, led by AstraZeneca Plc (NYSE:AZN), in a lawsuit accusing th...

Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...

Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Elevidys (delandistrogene moxeparvovec-rokl) to in...

Goldman Sachs has initiated coverage on Regenxbio Inc (NASDAQ:RGNX), citing the potential for the company’s gene therapy platform. The compan...

Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...

Italy’s antitrust regulator has initiated an investigation into several pharmaceutical giants, including Novartis AG (NYSE:NVS) and Roche Hol...

Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for ...